April 14 (Reuters) - Nektar Therapeutics and Bristol Myers Squibb said on Thursday they have jointly decided to end the global clinical development program for their cancer drug bempegaldesleukin in combination with Opdivo. (Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 USD | -5.99% | +18.94% | +177.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+177.88% | 288M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar, Bristol Myers end clinical trial program for cancer drug combo